Tofacitinib is a Janus kinase (JAK) inhibitor used to treat conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1][2]. Its primary mechanism of action involves blocking specific enzymes that play a role in the body's inflammatory and immune responses [1].
What does Tofacitinib treat?
Tofacitinib is approved for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate [2]. It is also indicated for active psoriatic arthritis and for adults with moderately to severely active ulcerative colitis [2].
How does Tofacitinib work?
Tofacitinib is a JAK inhibitor. It works by blocking the activity of Janus kinases (JAKs), which are enzymes involved in signaling pathways that regulate immune cell function and inflammation [1]. By inhibiting JAKs, tofacitinib reduces the production of cytokines that contribute to inflammation and immune system overactivity [1].
When does Tofacitinib patent expire?
The patent expiration timeline for tofacitinib can vary depending on specific patents and jurisdictions. Information on patent expiry dates is available through resources like DrugPatentWatch.com [3].
What are the risks associated with Tofacitinib?
Tofacitinib carries significant safety warnings, including an increased risk of serious infections, blood clots (in the lungs, legs, or arteries), heart attack, stroke, and certain cancers [2]. Patients taking tofacitinib are monitored for these risks [2].
How does Tofacitinib compare to other JAK inhibitors?
Tofacitinib is one of several JAK inhibitors available. Other JAK inhibitors, such as baricitinib and upadacitinib, also target JAK enzymes but may have different selectivity profiles for specific JAK subtypes, potentially leading to variations in efficacy and safety [1].
What are the common side effects of Tofacitinib?
Common side effects of tofacitinib can include upper respiratory tract infections, headache, diarrhea, nasopharyngitis, and increased blood cholesterol levels [2].
Can biosimilars be made for Tofacitinib?
The development of biosimilars for tofacitinib depends on patent expirations and regulatory pathways. Once patents expire and regulatory hurdles are cleared, biosimilar versions may become available, potentially offering alternative treatment options [3].
What clinical trials have been conducted for Tofacitinib?
Tofacitinib has undergone extensive clinical trials to establish its efficacy and safety for its approved indications. These trials have evaluated its performance in patients with rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, often comparing it to placebo or other standard treatments [1][2].
What is the recommended dosage for Tofacitinib?
Dosage for tofacitinib varies based on the specific condition being treated and the formulation (e.g., immediate-release or extended-release tablets) [2]. It is crucial to follow the prescribing physician's instructions regarding dosage and administration [2].
Who manufactures Tofacitinib?
Tofacitinib is manufactured by Pfizer Inc. [2].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.pfizer.com/
[3] https://www.drugpatentwatch.com/